Alcon secures EU approval of Travatan for treatment of Pediatric Glaucoma.
Alcon, the global leader in eye care and second-largest division of Novartis, announced that its treatment for patients with Glaucoma, Travatan (40µg/mL travoprost) Eye Drops Solution, has been granted an additional indication by the European Commission to decrease elevated intraocular pressure (IOP) in pediatric patients, aged two months to less than 18 years, with Ocular Hypertension or Pediatric Glaucoma. Travatan is currently indicated to decrease elevated intraocular pressure in adult patients with Ocular Hypertension or Open-angle Glaucoma.
Pediatric Glaucoma is responsible for 5% of childhood blindness worldwide. Patients suffering from Glaucoma have no cure and, if vision is lost, it cannot be restored. Elevated IOP is the only known modifiable risk factor for glaucoma and can typically be controlled with daily administration of eye drops, or in the most severe cases, with surgery.
.Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins